A Review on Quality by Design

Quality by Design (QbD) has arisen as a scientific and risk-oriented methodology for pharmaceutical development, serving as a bridge between industry and regulatory agencies to ensure consistent product quality. In contrast to conventional quality testing, Quality by Design (QbD) emphasizes the integration of quality into formulations and production processes from the outset. This methodology focuses on delineating the Target Product Profile (TPP) and Target Product Quality Profile (TPQP), identifying Critical Quality Attributes (CQAs), and evaluating the influence of Critical Material Attributes (CMAs) and Critical Process Parameters (CPPs) on product efficacy. The incorporation of design space, control strategy, and risk assessment tools into product lifecycle management facilitates ongoing enhancement. QbD, which has its roots in ICH guidelines Q8 (Pharmaceutical Development), Q9 (Quality Risk Management), and Q10 (Pharmaceutical Quality System), improves process comprehension, permits regulatory flexibility, lessens validation burdens, and minimises post-approval modifications. Through the use of instruments like Process Analytical Technology (PAT) and Design of Experiments (DoE), QbD guarantees reliable product development and facilitates quicker regulatory approvals. All things considered, QbD is a contemporary paradigm in pharmaceutical sciences that promotes creativity, dependability, and regulatory compliance in the creation and production of new drugs.